Key Insight: Patients committed to ongoing testing, data monitoring, and personalized care experience 90% more improvement than those who don’t.
Overview #
Based on over 500,000 data points collected over the last five years, this report highlights key health improvements achieved through Dripdok’s protocols, including blood chemistry, DNA methylation, disease risk reductions, and regenerative treatment outcomes.
Key Improvements Across Our Patient Cohort #
| Health Area | Improvement | Data Source |
|---|---|---|
| 10-year heart attack risk | 25–35% reduction (Framingham Risk Score) | Blood panels + wearable CVD monitoring |
| Insulin sensitivity | Fasting glucose normalized to 90–95 mg/dL, HbA1c -0.3–1.0% in 80% of patients | Blood panels |
| Thyroid Health | 35% of patients had elevated TSH; 75% normalized after treatment | Thyroid function panels |
| Memory/Neuroprotection | 33% increase in telomere length; memory improvement in 90% of patients | Cognitive testing (Creyos) |
| Sleep & Mental Health | 40% reduction in anxiety; improved sleep cycles | Wearable data, DSIP peptide cohort |
| Telomere Length | 30–35% increase | Epithalon + GHK-Cu cohort |
| Testosterone | 25–30% increase in men; 85% reported improved libido | Hormone panels |
| Pain Reduction | Significant reduction in soft tissue injury pain; enhanced cartilage regeneration | BPC-157 + TB-500 cohort |
| Biological Age (Best Case) | One patient reduced biological age to 27 at chronological age 65 | DNA methylation testing |
Key Finding #
Tech-savvy, data-driven patients experienced the best outcomes — most likely because they understood that health is not subjective but objective, and data allows the unseen to be seen.
Dripdok’s personalized regenerative therapies — including peptides, NAD+, and exosomes — have led to measurable, sustained improvements that compound over time for committed patients.
